Optimizing the Care of Patients Receiving CAR T-Cell Therapy
Patients with relapsed or refractory hematologic disorders like acute lymphoblastic leukemia and diffuse large B-cell lymphoma have poor outcomes and require novel effective therapies. Currently, CAR T-cell therapies have demonstrated significant responses in these contexts, but this immunotherapy is associated with unique toxicities, including cytokine release syndrome and neurologic toxicities, that need to be quickly identified for effective management. To ensure that health care professionals, including hematology/oncology nurses, are adequately prepared to deliver the necessary care, it is important that institutions have protocols in place with clear criteria and recommended therapeutic interventions so that staff receive comprehensive training that will lead to efficient delivery of multidisciplinary care and likely improve patient outcomes.
This information was originally presented at the NCCN 2018 Nursing Forum: Oncology Nursing in Hematologic Malignancies held in New York, New York, on September 21, 2018.
This educational program is designed to meet the educational needs of oncology nurses who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Describe what CAR T-cell therapy is and contexts for its use
- Outline grading criteria for CAR T-cell associated toxicities and corresponding therapeutic interventions
- Describe how to develop institutional standards to ensure efficient delivery of multidisciplinary care and improve outcomes for patients receiving CAR T-cell therapy
Lauren Spendley, NP
Dana-Farber Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Lauren Spendley, MSN, AGNP-BC
Celgene Corporation: Scientific Advisor
Juno Therapeutics: Scientific Advisor
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa G. Kimbro, MBA, CPA (employed by NCCN until August 10, 2018); Joan S. McClure, MS (employed by NCCN until August 1, 2018); Lisa Perfidio, MS; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Gary J. Weyhmuller, MBA, SPHR
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Mary A. Dwyer, MS, CGC; Ndiya Ogba, PhD
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.50 contact hours.
- 0.50 ANCC contact hours
- 0.50 Participation